Document Detail

Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs.
MedLine Citation:
PMID:  18208664     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Renin-angiotensin-aldosterone system has been demonstrated to be associated with both congestive heart failure (CHF) and atrial fibrillation (AF). This study investigated the effects of spironolactone, a kind of aldosterone antagonist, on atrial electrical remodeling and fibrosis in CHF dogs induced by chronic rapid ventricular pacing. METHODS: Twenty one dogs were randomly divided into sham-operated group, control group, and spironolactone group. In control group and spironolactone group, dogs were ventricular paced at 220 beats per minute for 6 weeks. Additionally, spironolactone at 15 mg x kg(-1) x d(-1) was given to dogs 1 week before rapid ventricular pacing until pacing stopped. Transthoracic and transoesophageal echocardiographic examinations were performed to detect structural and functional changes of the atrium. Swan2 Ganz floating catheters were used to measure hemadynamics variances. Atrial effective refractory period (AERP), AERP dispersion (AERPd), intra- and inter-atrium conduction time (CT) and intra-atrium conduction velocity (CV) were determined. The inducibility and duration of AF were also measured in all groups. Finally, atrial fibrosis was quantified with Masson staining. RESULTS: AERP did not change significantly after dogs were ventricular paced for 6 weeks. However, AERPd, intra- and inter-atrium CT increased significantly, and CV decreased apparently, which was negatively correlated to the atrial fibrosis (r = -0.74, P < 0.05). Simultaneously, left atriums were enlarged and cardiac hemadynamics worsened in pacing dogs. Although spironolactone could not affect cardiac hemadynamics effectively, it can obviously improve left atrial ejection fraction (P < 0.05). Spironolactone treatment did not alter AERP duration, but this medicine dramatically decreased AERPd (P < 0.05), shortened intra- and inter-atrium conduction time (P < 0.05), and increased atrium CV. Moreover, spironolactone decreased the inducibility and duration of AF (P < 0.05), as well as atrial fibrosis (P < 0.01) induced by chronic rapid ventricular pacing. CONCLUSION: Spironolactone contributes to AF prevention in congestive heart failure dogs induced by chronic rapid ventricular pacing, which is related to atrial fibrosis reduction and independent of hemadynamics.
Shu-sen Yang; Wei Han; Hong-yan Zhou; Guo Dong; Bai-chun Wang; Hong Huo; Na Wei; Yong Cao; Guo Zhou; Chun-hong Xiu; Wei-min Li
Related Documents :
20546154 - Bifocal right ventricular resynchronization for the failing right ventricle.
16438224 - A novel ex vivo heart model for the assessment of cardiac pacing systems.
9107184 - Verapamil reduces tachycardia-induced electrical remodeling of the atria.
12815304 - Change in distant atrial activation patterns during circumferential pacemapping of pulm...
2239714 - Angiographic assessment of the culprit coronary artery lesion before acute myocardial i...
22924634 - Reperfusion-induced myocardial dysfunction is prevented by endogenous annexin-a1 and it...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Chinese medical journal     Volume:  121     ISSN:  0366-6999     ISO Abbreviation:  Chin. Med. J.     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2008-01-22     Completed Date:  2008-04-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7513795     Medline TA:  Chin Med J (Engl)     Country:  China    
Other Details:
Languages:  eng     Pagination:  38-42     Citation Subset:  IM    
Department of Cardiology, First Clinical College of Harbin Medical University, Harbin, Heilongjiang 150001, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Atrial Fibrillation / prevention & control
Cardiac Volume
Collagen / analysis
Heart Atria / drug effects*,  pathology,  physiopathology
Heart Failure / drug therapy*,  pathology,  physiopathology
Hemodynamics / drug effects
Spironolactone / therapeutic use*
Reg. No./Substance:
52-01-7/Spironolactone; 9007-34-5/Collagen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Calpain I inhibition prevents atrial structural remodeling in a canine model with atrial fibrillatio...
Next Document:  The mechanism of signal transduction during vascular smooth muscle cell proliferation induced by aut...